Indications for ALOXI:
Prevention of acute and delayed nausea and vomiting due to initial and repeat courses of moderately emetogenic chemotherapy in adults. Prevention of acute nausea and vomiting due to initial and repeat courses of highly emetogenic chemotherapy in adults. Prevention of acute nausea and vomiting due to initial and repeat courses of emetogenic chemotherapy, including highly emetogenic cancer chemotherapy, in children 1 month–<17yrs. Prevention of post-op nausea and vomiting for up to 24hrs after surgery in adults.
≥17yrs: give 30mins prior to chemotherapy. 0.25mg IV as a single-dose over 30secs. Post-op: give immediately before anesthesia induction. 0.075mg IV over 10secs.
<1 month: not established. 1 month–<17yrs: give 30mins prior to chemotherapy. 0.02mg/kg IV as a single-dose over 15mins; max 1.5mg/dose.
Discontinue and treat if hypersensitivity reactions occur; do not reinitiate. Monitor for serotonin syndrome; discontinue and treat if occurs. Pregnancy. Nursing mothers.
Selective 5-HT3 receptor antagonist.
Increased risk of serotonin syndrome when concomitant with other serotonergic drugs (eg, SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, IV methylene blue).
Headache, constipation, bradycardia, QT prolongation, diarrhea, dizziness, tachycardia, hypotension.
Renal. Half-life: ~40 hours.
Single-use vial (0.075mg/1.5mL)—5; (0.25mg/5mL)—1